ICAM1 and hyperuricemia: Although several studies indicated that treatment with allopurinol attenuated the increase in intercellular adhesion molecule-1 (ICAM-1) levels after acute ischemic stroke or decreased hsCRP in asymptomatic hyperuricemia (29, 30), recent placebo-controlled RCTs demonstrated that treatment with allopurinol did not improve endothelial function, oxidative stress, and inflammation in patients with stage 3 CKD (31).